e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension: novel targets and drugs
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
D. Omiatek, F. Leifer, V. Malinin, J. Ong, T. Henn, Z. Li, R. Chapman, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada)
Source:
International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Session:
Pulmonary hypertension: novel targets and drugs
Session type:
Thematic Poster Session
Number:
2357
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Omiatek, F. Leifer, V. Malinin, J. Ong, T. Henn, Z. Li, R. Chapman, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada). Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension. Eur Respir J 2014; 44: Suppl. 58, 2357
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014
Impact of sepsis in respiratory mechanics of pulmonary arterial hypertension rat model. Preliminary results
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Smad1 deficiency and female gender contribute to the development of pulmonary hypertension
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Nebivolol and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept